Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain
Table 1
Characteristics of ITP patients treated with romiplostim.
the start of romiplostim treatment. defined as platelet count ≥50 109/L. from romiplostim onset. as platelet count ≥50 109/L for 24 consecutive weeks in the absence of any treatment for ITP. ITP: primary immune thrombocytopenia; IVIG: intravenous immunoglobulin.